TRPV4 is able to regulate tumor angiogenesis and vascular maturation, so GSK1016790A has been proposed to be used together with other anticancer drugs, such as cisplatin, to achieve more effective cancer therapy (Peters et al., 2017). Here, TRPV4 is linked to neoplasm.